



or

# Descargar Ahora

Descarga Gratis! Go to [descargar.easydocmerge.com](https://descargar.easydocmerge.com)



## Monophasic and Biphasic Shock for Transthoracic Conversion of Atrial Fibrillation: Systematic Review and Network Meta-analysis

**Article (PDF Available)** in Resuscitation 100 · January 2016 with 48 Reads

DOI: 10.1016/j.resuscitation.2015.12.009



1st **José Francisco Secorun In...**  
7.45 · Fundação Universitária de ...



2nd **Michele Dos Santos Gome...**  
5.34 · Pontifícia Universidade Cat...



3rd **Julie Shah**

+ 3



Last **Clarissa Garcia Rodrigues**

Show more authors

### Abstract

**Objectives:** Conduct a systematic review of the literature to compare the efficacy of different biphasic and monophasic shock waveforms technologies for transthoracic cardioversion of Atrial Fibrillation (AF). **Methods:** We searched PubMed, EMBASE, The Cochrane Library, LILACS and ClinicalTrials.gov databases for randomized clinical trials comparing two or more defibrillation waveforms when performing elective transthoracic cardioversion of AF. The outcomes assessed were 1st shock success, overall success, cumulative energy and number of shocks to restore Normal Sinus Rhythm. **Results:** Were included 23 trials involving 3046 patients, 5 biphasic and the monophasic waveform. Direct meta-analysis revealed that Biphasic waveforms have higher chance to achieve cardioversion in the 1(st) shock (OR: 3.2; 95% CI 2.2-4.7) and after a sequence of attempts (OR:2.4; 95% CI 1.5-3.9), requiring 296 less Joules (95% CI 356-237) and 0.74 less shocks (95% CI 1.03-0.44) when compared to Monophasic. Network meta-analysis showed no significant differences between the Biphasic technologies of PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear, in any of the four outcomes. **Conclusion:** The evidences points to a Biphasic waveform superiority over Monophasic to perform AF cardioversion, supporting current guidelines to use less energy when using a Biphasic defibrillator. It is suggested that the Biphasic defibrillators from PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear have similar efficacy and the use of any of them may result in similar chances, energy and number of shocks to achieve successful AF cardioversion.

Ad closed by  
**Google**

Stop seeing this  
ad

Why this ad? ⓘ

### Discover the world's research

- **11+ million** members
- **100+ million** publications
- **100k+** research projects

Join for free

**3 Figures**



Full-text (PDF)

Available from: [Michele Dos Santos Gomes Da Rosa](#), Feb 12, 2016

[Download full-text PDF](#)



Contents lists available at ScienceDirect

# Resuscitation

journal homepage: [www.elsevier.com/locate/resuscitation](http://www.elsevier.com/locate/resuscitation)

## Review article

# Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network meta-analysis<sup>☆</sup>



José Francisco Secorun Inácio<sup>a,b,\*</sup>, Michele dos Santos Gomes da Rosa<sup>c</sup>, Julie Shah<sup>d</sup>,  
Jeferson Rosário<sup>b</sup>, João Ricardo Nickenig Vissoci<sup>e</sup>, André Luiz Langer Manica<sup>a</sup>,  
Clarissa Garcia Rodrigues<sup>a</sup>

<sup>a</sup> Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, RS, Brazil

<sup>b</sup> Toth Tecnologia, Porto Alegre, RS, Brazil

<sup>c</sup> Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil

<sup>d</sup> Duke University, Durham, NC, United States

<sup>e</sup> Faculdade Ingá, Maringá, PR, Brazil

## ARTICLE INFO

### Article history:

Received 2 October 2015

Received in revised form 4 December 2015

Accepted 18 December 2015

### Keywords:

Monophasic defibrillator

Biphasic defibrillator

Cardioversion

Atrial fibrillation

Systematic review, Network meta-analysis

## ABSTRACT

**Objectives:** Conduct a systematic review of the literature to compare the efficacy of different biphasic and monophasic shock waveform technologies for transthoracic cardioversion of Atrial Fibrillation (AF). **Methods:** We searched PubMed, EMBASE, The Cochrane Library, LILACS and ClinicalTrials.gov database for randomized clinical trials comparing two or more defibrillation waveforms when performing elective transthoracic cardioversion of AF. The outcomes assessed were 1st shock success, overall success, cumulative energy and number of shocks to restore Normal Sinus Rhythm.

**Results:** Were included 23 trials involving 3046 patients, 5 biphasic and the monophasic waveform. Direct meta-analysis revealed that Biphasic waveforms have higher chance to achieve cardioversion in the shock (OR: 3.2; 95% CI 2.2–4.7) and after a sequence of attempts (OR: 2.4; 95% CI 1.5–3.9), requiring 296 J (95% CI 356–237) and 0.74 less shocks (95% CI 1.03–0.44) when compared to Monophasic. Network meta-analysis showed no significant differences between the Biphasic technologies of PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear in any of the four outcomes.

**Conclusion:** The evidence points to a Biphasic waveform superiority over Monophasic to perform cardioversion, supporting current guidelines to use less energy when using a Biphasic defibrillator. It suggested that the Biphasic defibrillators from PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear have similar efficacy and the use of any of them may result in similar chances, energy and number of shocks to achieve successful AF cardioversion.

© 2016 Elsevier Ireland Ltd. All rights reserved.

## Introduction

Electrical cardioversion for the treatment of Atrial fibrillation (AF) is classified as a Class I treatment when pursuing rhythm-control strategy (LOEB). Its benefits have been demonstrated when a rapid ventricular response to AF does not respond promptly to pharmacological strategies and contributes to other comorbidities (LOE C) and when it is associated with hemodynamic

instability (LOE C).<sup>1</sup> It is also known that biphasic shock waveforms need lower energy than monophasic shock waveform for transthoracic cardioversion of AF. Recommendations for initial energy have been set to 120 J for biphasic waveforms, and 200 J for monophasic waveforms.<sup>2</sup> Animal studies suggest that lower energy biphasic shocks decrease the risk of myocardial dysfunction.<sup>3</sup>

Overall, in guidelines and literature reviews, Biphasic waveform shocks are treated as equal, and possible differences between Biphasic waveform technologies have not yet been completely clarified. A recent systematic review of nine studies on the treatment of AF compared monophasic and biphasic techniques demonstrating better performance of the Biphasic, but no distinction of the biphasic technologies were evaluated reported.<sup>4</sup>

<sup>☆</sup> A Spanish translated version of the summary of this article appears as Appendix in the final online version at <http://dx.doi.org/10.1016/j.resuscitation.2015.12.009>.

\* Corresponding author at Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia, Registros Clínicos, Princesa Isabel Av 395, Santana, 90010-395 Porto Alegre, RS, Brazil.

E-mail address: [francisco@tothtecnologia.com.br](mailto:francisco@tothtecnologia.com.br) (J.F.S. Inácio).

<http://dx.doi.org/10.1016/j.resuscitation.2015.12.009>

0300-9572/©2016 Elsevier Ireland Ltd. All rights reserved.

Two major types of biphasic waveforms are known as Rectilinear Biphasic Waveform (RBW) and Biphasic Truncated Exponential (BTE). Different BTE manufactures can have different peak voltages, positive and negative cycle's durations and tilts. In both types of biphasic waveforms the defibrillator reads the patient's transthoracic impedance during energy delivery, and adjusts its outputs in order to deliver the selected energy to the patient. However they differ in how they adjust their output to compensate for the patient's impedance. Rectilinear Biphasic Waveform (RBW), developed by Zoll<sup>TM</sup>, has a 200 J limit and adjusts its internal impedance to deliver a constant current. One major Biphasic Transthoracic Exponential waveform is the ADAPTIV<sup>TM</sup> developed by PhysioControl<sup>TM</sup>. It has a 360 J limit and controls lead-edge voltages and adjusts pulse duration. Another major BTE waveform is the Philips SMART<sup>TM</sup> Biphasic, it has a 200 J limit, constant edge voltages and it controls pulse tilts and adjusts pulse duration.<sup>5–7</sup> A number of randomized control trials have evaluated the safety and performance of these technologies and others, yet further investigation is needed to better understand these differences. Thus, the aim of this study was to conduct a systematic review and network meta-analysis of randomized control trials to compare the efficacy of different biphasic waveforms and monophasic shock waveforms, applied through the thorax, for the conversion of Atrial fibrillation. The outcomes compared were Cumulative Energy, Number of Shocks, First Shock Success Rate and Overall Success Rate to restore normal sinus rhythm (NSR) in patients with AF undergoing elective cardioversion therapy.

## Methods

### Protocol and registration

This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement<sup>8</sup> and is registered in the Prospero database [CRD42014010479].

### Eligibility criteria

**Participants:** Patients diagnosed with AF, persistent or not, undergoing elective cardioversion.

**Interventions:** Studies where the cardioversion shock therapy delivered through the thorax in attempt to restore NSR was evaluated reporting the number of shocks delivered, the mean energy delivered and success rate to restore NSR.

**Comparison:** Group receiving any Biphasic shock technology compared to a group receiving Monophasic shock or group receiving one type of Biphasic technology compared to a group receiving other type of Biphasic technology.

**Outcomes:** The outcomes were Cumulative Energy representing the mean cumulative energy necessary to restore NSR, the number of shocks, representing the mean number of shock necessary to restore NSR, first shock success rate, representing the odds ratio to restore NSR in the first shock attempt and overall success rate to restore NSR representing the odds ratio to restore NSR after all shocks attempt.

**Types of Study:** Studies designed as a Randomized Clinical Trial (RCT). No language limits were used. Studies with duplicated population and those that did not provide the type of biphasic technology used were excluded.

### Information sources

A search was performed using the following electronic databases: PubMed, EMBASE, Cochrane Central Registry of Controlled Trials, ClinicalTrials.gov, and Lilacs. The search included references

of manually included articles and citation analysis of the included studies was performed using Google Scholar.

### Search

The initial search comprised the Mesh terms *Atrial fibrillation electric countershock*, *clinical trial* and their related entry terms. The search date was limited between 1/01/2000 and 6/31/2014. The complete search strategy used for the PubMed database is shown in Appendix Table 1. The searches were updated on 9/5/2016 to verify if newer publications were available.

### Study selection

Titles and abstracts of the retrieved articles were independently evaluated by 2 reviewers (JFI and MG). Abstracts that did not provide enough information regarding the eligibility criteria kept for full-text evaluation. Reviewers independently evaluated full-text articles and determined study eligibility. Disagreements were solved by consensus and when a consensus could not be reached a third reviewer (AM) was used.

### Risk of bias

Risk of bias was evaluated according to the PRISMA statement recommendation. Study quality assessment included: selection bias items, such as adequate sequence generation, and allocation concealment; performance of bias items, such as blinding of participants and personnel, and blinding of outcome assessment; attrition bias evaluated through the assessment of incomplete outcome data; reporting of bias by the assessment of selective reporting; and other sources of bias. Two reviewers (JFI and MG) independently performed quality assessment, and disagreements were solved by consensus or by a third reviewer (AM).

### Data extraction

Two reviewers (JFI and MG) independently conducted the extraction and disagreements were solved by the third reviewer (AM). Characteristics such as cumulative energy, number of shocks and first shock success to restore normal sinus rhythm retrieved from the included studies. In studies where cross-analysis was conducted, the data was collected before the cross-analysis was performed. Cumulative success rate and study up energy protocol were used to calculate the cumulative energy and the number of shocks in studies that did not report these outcomes directly.

### Data analysis

Considering that the studies have similar designs, same outcomes and different upscaling energy protocols, we conducted a direct meta-analysis pooling the results using a random-effects model with mean differences for continuous outcomes such as cumulative energy and number of shocks and odd ratios outcomes such as shock success and overall success, and calculated 95% confidence intervals and two-sided *P* values. The Cochran Q test was used to assess heterogeneity and a value of *P* less than 0.1 was considered statistically significant. The *I*<sup>2</sup> testing was also used to measure the magnitude of the heterogeneity. The possibility of bias across studies was also evaluated using funnel plot of each of the trials size against the standard error (SE).

A network meta-analysis was also used, allowing for the comparison of two trials that have at least one treatment in common. The Bayesian Markov-chain Monte Carlo method using statistical software R studio and JAGS package was used. The results

were expressed with mean differences for cumulative energy and number of shocks and odd ratios for 1st shock success and overall success with 95% credible intervals (CrI).

## Results

### Study selection

Based on this search strategy, a total of 2651 citations were identified and reviewed. After evaluating those against the predefined eligibility criteria, a total of 23 studies were included in this systematic review involving 3046 patients, 5 different biphasic waveform technologies and 7 types of monophasic waveform. The complete study workflow is shown in Fig. 1.

### Studies characteristics

Table 1 summarizes the included studies characteristics. The energy protocol is the predefined upscaling energy protocol of attempts to restore normal sinus rhythm and differences among studies were observed, where the majority had predefined protocols starting with a lower energy and upscaling the energy until the highest energy available was used in the last attempt. In one particularly study the energy dose was defined by the physician individually for each patient and in another study the energy dose was chosen proportionally to the patient weight. Criteria to define successful cardioversion also vary; studies may consider a valid conversion an immediate conversion, a conversion that holds at least a number of consecutive sinus beats or a conversion that sustains at least one to two minutes of normal sinus rhythm. PhysioControl Biphasic (BTE1) is present in 11 studies being applied in 706 patients, Philips SMART Biphasic (BTE2) in 5 studies and 292 patients, Welch Allyn Biphasic (BTE3) in two studies and 93 patients, Nihon-Koden Biphasic (BTE4) in one study and 100 patients and the Zoll Rectilinear Biphasic (RBW) in 9 studies and 655 patients. The Monophasic Damped Sine waveform (MDS) was present in 19 studies and 1200 patients, appearing in seven different forms: PhysioControl Lifepak 9 Monophasic (MDS1), PhysioControl Lifepak 12 Monophasic (MDS2), GE Responder 3000 Monophasic (MDS3), GE CardioServ Monophasic (MDS4), HP CodeMaster XL Monophasic (MDS5), Zoll Monophasic (MDS6) and Chirana BPD 13 Monophasic (MDS7). The use of several pharmacological antiarrhythmic therapies was identified across studies where the patient could be receiving one or more drugs prior to the procedures.

### Risk of bias within studies

In relation to selection bias most trials presented unclear descriptions. Eleven studies did not report the method for allocation concealment and 13 failed to report the method for random sequence generation.

For performance bias, because transthoracic elective cardioversion is performed with the patient under sedation, and blinding of the defibrillator is a challenge, single-blinded studies were considered to be of low risk of bias. Only two studies were considered to be of high risk. In relation to detection bias, 13 studies lacked information regarding the blinding of the outcome assessment, and three were considered high risk.

Attrition bias was analyzed by evaluating incomplete outcomes data. Most studies presented low risk of bias (16 trials), three trials were considered to have high risk of bias, and in three trials the risk of bias was unclear. Additionally, among the 23 studies included, 17 had low risk of reporting bias (analyzed by the evaluation of

selective reporting) and six had a high risk of reporting bias. The complete risk of bias results is shown in Appendix Table 2.

### Qualitative analysis—Individual studies

Of the 23 trials included, 8 compared BTE1 and MDS. Ten studies reported BTE1 as superior for 1st shock success, overall success, cumulative energy and number of shocks to restore NSR.<sup>9–11</sup> One study reported BTE1 as superior to MDS for overall success and cumulative energy but did not report statistical results regarding shock success and number of shocks.<sup>12</sup> One study demonstrated BTE1 as superior for cumulative energy and number of shocks, and no significant difference for overall success. It did not evaluate shock success since the study did not follow a predefined energy protocol; the energy was set at the discretion of the physician. In addition, one study showed BTE1 as superior for overall success and cumulative energy, and reported no significant difference in the number of shocks and did not evaluate 1st shock success. Also one study had a BTE1 protocol (50–100–150–175 J) using 1/3 the energy of the MDS protocol (100–200–300–360 J) presenting significant difference between BTE1 and MDS for 1st shock success, overall success and number of shocks and BTE1 as superior for cumulative energy.<sup>15</sup> Finally, one study reported that the group that received BTE1 at any point had a significantly higher overall success rate.<sup>16</sup>

Four studies were reviewed that compared BTE2 to MDS. One study reported BTE2 as superior to MDS for 1st shock success, cumulative energy and number of shocks and found no significant difference for overall success.<sup>17</sup> One study showed no significant difference for 1st shock success, overall success or number of shocks, and found BTE2 to be superior for cumulative energy. Another study demonstrated BTE2 as superior to MDS for 1st shock success, and showed no significant difference for overall success but did not evaluate cumulative energy or number of shocks.<sup>19</sup> One study reported BTE2 as significantly superior to MDS for overall success and cumulative energy, but did not evaluate 1st shock success or number of shocks.<sup>20</sup>

Five studies were reviewed comparing RBW to MDS. Two studies reported no significant difference for 1st shock success and overall success, and reported RBW as superior to MDS for cumulative energy.<sup>21,22</sup> One study found no significant difference for 1st shock success, overall success, or number of shocks and reported RBW superior only for cumulative energy.<sup>23</sup> One study reported RBW superior for overall success and cumulative energy but did not evaluate 1st shock success or number of shocks.<sup>20</sup> One study reported RBW as superior to MDS for 1st shock success and overall success but did not evaluate cumulative energy or number of shocks.<sup>24</sup>

Three studies were reviewed comparing BTE1 to RBW.<sup>25–27</sup> Two studies reported no significant difference for 1st shock success and overall success. One study reported no significant difference in the number of shocks and RBW as superior to BTE1 for cumulative energy using the Student's *t* test approach.<sup>27</sup> One study reported no significant difference for number of shocks and BTE1 as superior to RBW for cumulative energy using the Wilcoxon rank-sum test approach.<sup>25</sup>

Two studies were reviewed comparing BTE2 to RBW. Neither study showed significant differences for overall success. One study had no significant difference for 1st shock success, overall success, cumulative energy or number of shocks.<sup>28</sup> One study reported BTE2 as superior to RBW for cumulative energy.<sup>20</sup>

Two studies evaluated BTE3 versus MDS. One study reported no significant difference for 1st shock success or overall success and reported BTE3 as significantly superior to MDS for cumulative energy and number of shocks.<sup>29</sup> One study presented cumulative energy and number of shocks results however no statistical differences were calculated between groups.<sup>30</sup>

**Table 1**

Summary of characteristics of included studies.

First Author and Year of publication	Study arms	No. of patients	Energy protocol (J)	Successful cardioversion criteria	Mean age ± SD (years)	Mean weight or BMI ± SD
Deakin 2013 <sup>28</sup>	RBW	<i>n</i> = 101	50–100–150–200–200	Converted to sinus rhythm immediately after shock and remained at that rhythm for 60 s	65.5 (60.0–70.2) <sup>a</sup>	90.2 (80.0–103.0)
	BTE2	<i>n</i> = 99	50–100–150–200–200		68.0 (61.5–72.0) <sup>a</sup>	88.9 (80.2–98.0)
Stanaitienė 2008 <sup>11</sup>	MDS1	<i>n</i> = 112	100–200–300–360	ECG registered sinus rhythm within 30 s after shock	64.9 ± 9.28	89.5 ± 15

See all >  
31 ReferencesSee all >  
3 Figures

Share

Download full-text PDF

Manegold 2007 <sup>21</sup>	MDS4	<i>n</i> = 21	200–300–360–360	Not reported	70.0 ± 10.0	27 ± 4 kg
Kawabata 2007 <sup>15</sup>	RBW	<i>n</i> = 23	100–150–200–200	Restored sinus rhythm for 1 h after the shock	60.1 ± 13.3	26.6 ± 4.8
	MDS5	<i>n</i> = 77	100–200–300–360			
	BTE1	<i>n</i> = 77	50–100–150–175		55.1 ± 13.5	26.5 ± 3.8
Ambler 2006 <sup>29</sup>	MDS5	<i>n</i> = 68	100–200–300–360–360	Not reported	70 (22–87) <sup>†</sup>	83 (42–113) kg <sup>†</sup>
Skulec 2006 <sup>13</sup>	BTE3	<i>n</i> = 60	70–100–150–200–300	Sinus rhythm restoration persisted >30 s after shock	67.2 ± 10.9	27.3 ± 3.5
	MDS3	<i>n</i> = 70	At discretion of physician			
Alatawi 2005 <sup>25</sup>	BTE1	<i>n</i> = 71	At discretion of physician	Conversion to sinus rhythm for at least 1 minute	68.6 ± 11.7	27.6 ± 3.0
	RBW	<i>n</i> = 71	50–75–100–120–150–200		67.6 ± 12.9	31.8 ± 6.8
	BTE1	<i>n</i> = 70	50–70–100–125–150–200–300–360		65.3 ± 14.5	30.2 ± 6.1
Kosior 2005 <sup>14</sup>	MDS4	<i>n</i> = 22	2 J/kg–360–360	Sinus rhythm was maintained for >2 h after the procedure	61.3 ± 9.1	Not reported
Kim 2004 <sup>26</sup>	BTE1	<i>n</i> = 26	2 J/kg–360–360	Restoration of sinus rhythm lasting >5 s after defibrillation	62.1 ± 10.5	84.9 ± 20
	RBW	<i>n</i> = 71	50–100–150–200		64 ± 15.2	
	BTE1	<i>n</i> = 74	50–100–150–200–360		65 ± 14.8	83.7 ± 19

Table 1 (Continued)

First Author and Year of publication	Study arms	No. of patients	Energy protocol (J)	Successful cardioversion criteria	Mean age $\pm$ SD (years)	Mean weight or BMI $\pm$ SD
Siaplaouras 2004 <sup>23</sup>	MDS6	$n = 108$	200–300–360–360	Termination of AF with at least 2 consecutive sinus beats	$65 \pm 10$	
Santomauro 2004 <sup>20</sup>	RBW MDS6	$n = 108$ $n = 18$	120–150–200–200 100–200–300–360–360	Sinus rhythm restoration for at least 30 s	$66 \pm 10$ $55.4 \pm 14$	
Koster 2004 <sup>9</sup>	RBW BTE2 MDS2	$n = 22$ $n = 24$ $n = 37$	75–100–150–200–200 70–100–150–200–200 70–100–200–360	Absence of AF after delivered shock, even if short-lived	$55.6 \pm 7$ $54.8 \pm 9.2$ $63.2 \pm 15.8$	$80.5 \pm 19$
	BTE1	$n = 35$	70–100–200–360		$69.6 \pm 10.9$	$80.4 \pm 15$
Page 2002 <sup>17</sup>	MDS5	$n = 107$	100–150–200–360	Two consecutive P waves uninterrupted by AF occurring any time within 30 s of the shock	$65 \pm 13$	$88 \pm 24$ kg
	BTE2	$n = 96$	100–150–200–200		$65 \pm 14$	$87 \pm 19$ kg
Marinsek 2003 <sup>18</sup>	MDS5	$n = 40$	100–200–300–360	Atrial P wave was unmistakably identified >30 s after the shock	$67 \pm 8$	$84 \pm 18$ kg
	BTE2	$n = 43$	70–100–150–200		$69 \pm 6$	$79 \pm 14$ kg
Neal 2003 <sup>27</sup>	RBW	$n = 53$	50–100–200–200	Presence of P waves, a captured atrial paced rhythm, or junction rhythm for 3 consecutive beats	$63.0 \pm 16.0$	$93.9 \pm 25$
	BTE1	$n = 48$	50–100–200–200		$60.0 \pm 16.0$	$96.3 \pm 28$
Scholten 2003 <sup>22</sup>	MDS5	$n = 109$	200–360	Sinus rhythm restored for more than five seconds	$59.9 \pm 14.0$	$82.5 \pm 19$
	RBW	$n = 118$	120–200		$59.6 \pm 12.4$	$81.9 \pm 20$



Ricard 2001 <sup>19</sup>	MDS5	<i>n</i> = 27	150–360	Sinusrhythm was restored for a period >5 min	66 ±12	77± 17 k
	BTE2	<i>n</i> = 30	150–150		69 ±10	79± 14 k
Mittal 2000 <sup>24</sup>	MDS6	<i>n</i> = 77	100–200–300–360	Conversion of AF to sinus rhythm for >30s after the shock	66 ±12	93± 24 k
	RBW	<i>n</i> = 88	70–120–150–170		65 ±12	89± 21 k
Kmec 2006 <sup>31</sup>	MDS7	<i>n</i> = 100	200–300–360–360	Conversion of AF to sinus rhythm for >60s after the shock	62.6 ±7.7	29.6+4.8
	BTE4	<i>n</i> = 100	100–120–270–270		63.6 ±8.5	30.4+5.3
Khaykin 2003 <sup>16</sup>	MDS2	<i>n</i> = 28	360	At least 5 consecutive beats of atrial origin without evidence of fibrillatory activity during diastole	59.7 ±10.8	96.9 ± 29
Neumann 2004 <sup>10</sup>	BTE1	<i>n</i> = 28	150–200–360	Conversion of AF to sinus rhythm for at least 30 s after shock delivery	58.3 ±14.6	94.5 ± 27
	MDS1	<i>n</i> = 57	100–200–360		63.5 ±11	Not reported
	BTE1	<i>n</i> = 61	100–200–360		61.5 ±11	
Deakin 2006 <sup>30</sup>	MDS5	<i>n</i> = 25	100–200–300–360–360	Evaluated the time between the shock and the first P wave	71.0 (45–84) <sup>*</sup>	82.8 (55–139)
	BTE3	<i>n</i> = 33	70–100–150–200–300		68.5 (50–86) <sup>†</sup>	83.0 (83–139)
Kirchhof 2005 <sup>12</sup>	MDS1	<i>n</i> = 97	50–100–200–300–360	Presence of sinus rhythm immediately after the shock	63 ±1	27.2+0.4
	BTE 1	<i>n</i> = 104	50–100–200–300–360		63 ±1	27.3+0.4

BTE1: PhysioControl Biphasic, BTE2: Philip\$SMART Biphasic, BTE3: Welch-Allyn Biphasic, BTE4: Nihon-Koden Biphasic, RBW: Zoll Rectilinear Biphasic, MDS1: Physi Monophasic, MDS3: GE Responder 3000 Monophasic, MDS4: GE Cardioserv Monophasic, MDS5: HPCode Master XL Monophasic, MDS6: Zoll Monophasic, MDS7: C Index.

<sup>\*</sup> Variable represented in median (minimum, maximum).

<sup>†</sup> Reported data not separated by study groups.






Fig. 1. Study selection workflow diagram.

One study showed BTE4as significantly superior toMDS for all four outcomes.<sup>31</sup>

#### Synthesis of results—Direct meta-analysis

Meta-analysis of 15 studies compared MDS to Biphasic, where the Biphasic waveforms were divided into subgroups. Results revealed that Biphasic waveforms have superiority in 1st shock success (OR: 3.2; 95% CI 2.2–4.7) (Fig. 2a), overall success (OR: 2.4; 95% CI 1.5–3.9) (Fig. 2b), achieves cardioversion using 296 less Joules (95% CI 356–237) (Fig. 2c) and using 0.74 less shocks (95% CI 1.03–0.44) (Fig. 2d) when compared to Monophasic.

When considering the subgroups, the PhysioControl has superiority in 1st shock success (OR: 4.1; 95% CI 1.8–9.3) (Fig. 2a) and superiority in overall success (OR: 4.6; 95% CI 1.37–15.8) (Fig. 2b) achieves cardioversion using 256 less Joules (95% CI 336–176) (Fig. 2c) and using 0.89 less shocks (95% CI 1.38–0.39) (Fig. 2d) when directly compared to Monophasic. Philips SMART has superiority in 1st shock success (OR: 4.5; 95% CI 2.8–7.3) (Fig. 2a), achieves cardioversion using 302 less Joules (95% CI 405–198) (Fig. 2c) and using 0.71 less shocks (95% CI 1.35–0.07) (Fig. 2d) when directly compared to Monophasic. ZOLL Rectilinear has superiority in 1st shock success (OR: 2.6; 95% CI 1.05–6.4) (Fig. 2a) and achieves cardioversion using 320 less Joules (95% CI 537–104) (Fig. 2c) when directly compared to Monophasic.

Two meta-analyses compared directly Biphasic waveforms and the results are presented in Table 2. Meta-analysis of 3 studies compared the Biphasic waveforms from PhysioControl Biphasic and

Zoll Rectilinear (BTE1xRBW) and meta-analysis of 2 studies compared Philips SMART Biphasic versus Zoll Rectilinear (BTE2xRBW) and in the pooled results of both meta-analyses no significant difference in any of the outcomes were revealed, indicating similar efficacy.


#### Risk of bias across studies

Heterogeneity evidence was found amongst studies comparing Biphasic with Monophasic (Fig. 2). For first shock success the  $I^2$  inconsistency was 66%, for overall success 50%, cumulative energy 84% and number of shocks 90%. When evaluating subgroups homogeneity was found in studies comparing Philips SMART Biphasic with Monophasic for the outcomes first shock success ( $I^2 = 0\%$ ) and overall success ( $I^2 = 0.4\%$ ).

For studies comparing Biphasic technologies directly, homogeneity is suggested for all four outcomes (Table 2).

#### Synthesis of results—Network meta-analysis

In the network analysis, 581 patients received PhysioControl Biphasic shock, 292 received Philips SMART Biphasic, 632 received ZOLL Rectilinear Biphasic and 866 received Monophasic Dampp Sine shock, summing up to a total of 2371 patients. Fig. 3 shows the network of comparisons. The width of the lines is proportional to the number of trials comparing each pair of treatments, and size of each node is proportional to the number of patients. A dashed line represents an indirect comparison.



**Fig. 2.** Comparison between Biphasic and Monophasic, sub-grouped by Biphasic type—(a) First shock success rate. (b) Overall success rate. (c) Cumulative Energy to achieve success. (d) Number of shocks to achieve success.

**Table 2**  
Direct meta-analysis between biphasic waveforms: BTE1 × RBW and BTE2 × RBW.

Comparison	Number of studies	Effect size [95% CI]	1st Shock success odds ratio	Overall success odds ratio	Cumulative energy mean difference	Number of shocks mean difference
BTE1 × RBW	3 [25–27]	Effect size [95% CI] Heterogeneity: $P, I^2$	0.90 [0.52; 1.57] 0.19, 40%	1.39 [0.42; 4.56] 0.48, 0%	23.5 [−4.88; 51.88] J 0.40, 0%	0.15 [−0.0 0.40, 0%
BTE2 × RBW	2 [20, 28]	Effect size [95% CI] Heterogeneity: $P, I^2$	0.88 [0.45; 1.76] 0.34, 0%	0.70 [0.18; 2.69] 0.28, 13%	15.2 [−77.7; 108.2] J 0.11, 60%	0.10 [−0.4 0.11, 60%

BTE1: PhysioControl Biphasic, BTE2: Philips SMART Biphasic, RBW: Zoll Rectilinear Biphasic.

Table 3 shows the results of the Network Meta-analysis. Through the network meta-analysis it was possible to indirectly compare PhysioControl Biphasic with Philips SMART Biphasic. Similar to the direct meta-analysis results, PhysioControl Biphasic was significantly superior to Monophasic in the 4 outcomes. Both Philips SMART Biphasic and Zoll Rectilinear Biphasic were superior to Monophasic in 3 outcomes (1st shock success, cumulative energy and number of shocks). There were no significant differences in

any of the 4 outcomes in comparisons between any of the Bip waveforms.

## Discussion


The evidence regarding the efficacy of Biphasic waveforms to convert AF to normal sinus rhythm, is sufficiently to indicate superiority compared to Monophasic waveforms and, although

**Table 3**

Network meta-analysis comparing BTE1, BTE2, RBW and MDS: 1st shock success, overall success, cumulative energy and number of shocks.

Waveform	1st Shock success, odds ratio [95% CrI]		
	MDS	BTE1	BTE2
BTE1	3.7 [1.9; 7.4]		
BTE2	3.9 [1.7; 9.2]	1.1 [0.38; 3.0]	
RBW	3.4 [1.7; 6.7]	0.9 [0.42; 1.9]	0.85 [0.34; 2.1]
	Overall success, odds ratio [95% CrI]		
BTE1	4.8 [1.7; 16]		
BTE2	1.9 [0.57; 8.1]	0.4 [0.07; 2.5]	
RBW	2.4 [0.85; 7.9]	0.5 [0.14; 2.0]	1.3 [0.27; 5.5]
	Cumulative energy, mean difference [95% CrI], (J)		
BTE1	−258.1 [−340.1; −179.4]		
BTE2	−282.9 [−399.9; −177.1]	−24.4 [−150.6; 97.5]	
RBW	−286.4 [−376.5; −201.9]	−28.4 [−116.8; 59.6]	−3.5 [−114.6; 112.2]
	Number of shocks, mean difference [95% CrI]		
BTE1	−0.79 [−1.26; −0.32]		
BTE2	−0.67 [−1.29; −0.04]	0.11 [−0.60; 0.86]	
RBW	−0.74 [−1.27; −0.23]	0.04 [−0.50; 0.57]	−0.07 [−0.77; 0.61]

BTE1: PhysioControl Biphasic, BTE2: Philips SMART Biphasic, RBW: Zoll Rectilinear Biphasic, MDS: Monophasic Damped Sine, CrI: Credible Interval.

**Fig. 3.** Network of Clinical Trials comparing defibrillation waveforms for Atrial fibrillation cardioversion—Solid lines represent direct comparison trials and dashed lines represent indirect comparisons. BTE1: PhysioControl Biphasic, BTE2: Philips SMART Biphasic, RBW: Zoll Rectilinear Biphasic, MDS: Monophasic Damped Sine.

this was previously addressed recently<sup>4</sup> the analysis was limited to pool Odds Ratio from the first shock success rate and the Biphasic waveforms were not discriminated. Our review identified similar evidence and it was able to extend the analysis for additional outcomes such as overall success, cumulative energy and number of shocks to restore sinus rhythm. Were identified 15 clinical trials comparing Biphasic with Monophasic, with a total of 2130 patients, and all studies reported significant Biphasic superiority in at least one of the four outcomes. These studies were of variable quality and methodological heterogeneous, specially regarding the energy sequence protocol, where the protocols could be the same for Biphasic and Monophasic groups, or the Biphasic group protocol could be slightly lower than the Monophasic group or even the Biphasic group protocol could be half the Monophasic group.

The pooled results provided evidence that the Biphasic waveform is significantly superior than Monophasic in the four outcomes, and therefore is suggested that Biphasic has superior efficacy over Monophasic. Considering that in all studies, the first shock energy of the Biphasic groups were always equal or slightly lower than the Monophasic, it is possible to assume that Biphasic have a higher chance to convert an AF with the same, or slightly lower, energy. Also the Biphasic, considering a sequence of shocks attempts to convert AF, needs lower cumulative energy and number of shocks to achieve success. Finally, for the overall success it wouldn't be expected significantly different chances, assuming that Monophasic can achieve success at some point, given more attempts and elevated energy, but the pooled results suggests that

the use of Monophasic will lower the chances to achieve AF cardioversions after all shocks attempts are tried.

When assessing efficacy between Biphasic, it was identified three clinical trials comparing PhysioControl Biphasic against Zoll Rectilinear Biphasic and two trials comparing Philips SMART Biphasic against Zoll Rectilinear Biphasic. The energy protocols showed homogeneity in these trials, possible because the Biphasic groups between studies, had the same energy sequence protocol at least in the four initial steps. Through a network meta-analysis it was possible to aggregate these trials strictly comparing Biphasic waveforms with the trials comparing Biphasic with Monophasic, allowing to generate an indirect comparison between PhysioControl Biphasic and Philips SMART Biphasic and resulting in sufficient evidence to establish the relative efficacy of these three technologies. In the network results there was no significant difference in any of the four outcomes, indicating that whether using PhysioControl, Philips SMART or Zoll Rectilinear there would be equal chances to convert AF in the first attempt, equivalent chances to convert after all attempts and the same cumulative energy and number of shocks would be needed to achieve successful cardioversion and thus suggesting similar efficacy.

Biphasic defibrillators in general have the capacity to read patient's transthoracic impedance and with this information, they can adjust its outputs according to the patient, increasing the efficacy to achieve cardioversion. Although PhysioControl, Philips SMART and Zoll Rectilinear use different circuit topologies and control methods in order to generate its waveform output, the individual particularities did not result in differential efficacy in this review.

### Limitations

Although the Monophasic defibrillators share the common characteristic of using the same passive circuit topology, with adjustment regarding the patient transthoracic impedance during the shock therapy delivery, the components values used, especially the high voltage capacitor capacitance and the current shaping inductor inductance and resistance, vary from one Monophasic manufacturer to other. This will result in Monophasic waveforms that are underdamped, critically damped or overdamped for different patient's transthoracic impedance. In this review, the possible efficacy differences between the Monophasic due to these differences were not considered.

Also, the dependence of the four outcomes was not evaluated. It is possible that the number of shocks and cumulative energy

have an opposite relationship and that a study protocol designed to start with a higher initial energy may tend to have a higher first shock success rate but also a higher cumulative energy result.

Additionally, skew was identified in the outcomes cumulative energy and number of shocks in some studies, specifically studies where the energy protocol had a low number of shocks. Even though the predefined statistical methods required the variables to be as close to a normal distribution, for these cases we accepted a level of skewness to apply the statistical evaluation.

No possible heterogeneity between studies associated with differences in the patients' characteristics, such as age, body mass index, weight or AF duration, were evaluated.

## Conclusion

Evidence points to a Biphasic waveform superiority over Monophasic to perform AF cardioversion, supporting current guidelines recommendations to use less energy when using a Biphasic defibrillator, that is, start with 120 J when using Biphasic and start with 200 J when using Monophasic.<sup>2</sup>

The energy output adjustment method by monitoring the patient's transthoracic impedance, inherent to the Biphasic waveforms, is relevant when performing cardioversion of Atrial fibrillation, but the three methods from different manufacturers evaluated (PhysioControl, Philips SMART and ZOLL Rectilinear) suggests similar efficacy and the use of any of them may result in similar chances of energy and number of shocks to achieve successful AF cardioversion.

## Conflict of interest statement

No conflicts of interest to declare.

## Acknowledgments

There were no funding sources to this study.

## References

- January C, Wann L, Alpert J, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. *Circulation* 2014;129:2262–77.
- Link M, Atkins D, Passman R, et al. Part 6: electrical therapies: automated external defibrillators, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2010;122:p706–19.
- Tang W, Weil MH, Sun S, et al. The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function. *J Am Coll Cardiol* 1999;34:p815–22.
- Al-Khatib SM, Allen Lapointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. *Ann Intern Med* 2014;160:p760–73.
- ZOLL Medical Corporation. Zoll Medical Corporation website 2014. Available from (<http://www.zoll.com/medical-technology/defibrillation/rectilinear-biphasic-technology/>) [Online, cited 2014 08 20].
- Medtronic Physio-Control Corp. Defibrillation with ADAPTIV™ biphasic technology 2002. Available from: <http://www.lifepak.gr/brochures/Adaptiv%20Biphasic%20Summary%20Booklet.pdf>. [Online, cited 2014 08 20].
- Koninklijke Philips Electronics N.V. Philips SMART biphasic therapy—application note 2010. Available from ([http://incenter.medical.philips.com/doclib/enc/fetch/2000/4504/577242/577243/577245/577817/577869/SMARTBiphasic\\_ApplicationNote\\_\(ENG\).pdf?fnodeid%3d578140%26vernum%3d3](http://incenter.medical.philips.com/doclib/enc/fetch/2000/4504/577242/577243/577245/577817/577869/SMARTBiphasic_ApplicationNote_(ENG).pdf?fnodeid%3d578140%26vernum%3d3)) [Online, cited 2014 08 20].
- Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- Koster R, Dorian P, Chapman F, Schmitt P, O'Grady S, Walker R. A randomized trial comparing monophasic and biphasic waveform shocks for cardioversion of atrial fibrillation. *Am Heart J* 2004;147:pe1–e7.
- Neumann T, Erdogan A, Reiner C, et al. Ambulatory electrocardioversion: fibrillation by means of biphasic versus monophasic shock delivery. A prospective randomized study. *Z Kardiol* 2004;93:p381–7.
- Stanaitiene G, Babarskiene R. Impact of electrical shock waveform and electrode positions on efficacy of direct current cardioversion for atrial fibrillation. *Medicina (Kaunas)* 2008;44:p665–72.
- Kirchhof P, Mönnig G, Wasmer K, et al. A trial of self-adhesive patch electrode and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). *Eur Heart J* 2005;26:1292–7.
- Skulec R, Belohlavek J, Kovarnik T, et al. Serum cardiac markers for tachycardia and monophasic electrical cardioversion for supraventricular tachycardia—a randomized study. *Resuscitation* 2006;70:423–31.
- Kosior D, Opolski G, Tadeusiak W, et al. Serum troponin I and myoglobin levels versus biphasic transthoracic shocks for cardioversion of persistent atrial fibrillation. *Pacing Clin Electrophysiol* 2005;28:s128–32.
- Kawabata V, Vianna C, Moretti M, et al. Monophasic versus biphasic waveform shocks for atrial fibrillation cardioversion in outpatients with concomitant amiodarone therapy. *Europace* 2007;9:p143–6.
- Khaykin Y, Newman D, Kowalewski M, Korley V, Dorian P. Biphasic monophasic cardioversion in shock-resistant atrial fibrillation: a randomized clinical trial. *J Cardiovasc Electrophysiol* 2003;14:p868–72.
- Page R, Kerber R, Russell J, et al. Biphasic versus monophasic shock wave for conversion of atrial fibrillation: the results of an international randomized double-blind multicenter trial. *Am Coll Cardiol* 2002;39:1956–63.
- Marinsek M, Larkin G, Zohar P, et al. Efficacy and impact of monophasic biphasic countershocks for transthoracic cardioversion of persistent atrial fibrillation. *Am J Cardiol* 2003;92:p988–91.
- Ricard P, Lévy S, Boccaro G, Lakhal E, Bardy G. External cardioversion of atrial fibrillation: comparison of biphasic versus monophasic waveform shocks. *Europace* 2001;3:p96–9.
- Santomauro M, Borrelli A, Ottaviano L, et al. Transthoracic cardioversion in patients with atrial fibrillation: comparison of three different waveform shocks. *Heart J Suppl* 2004;5:p36–43.
- Manegold I, Israel C, Ehrlich J, et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator: a randomized comparison of monophasic and biphasic shock energy applied. *Eur Heart J* 2007;28:1731–8.
- Scholten M, Szili-Torok T, Klootwijk P, Jordaens L. Comparison of monophasic and biphasic shocks for transthoracic cardioversion of atrial fibrillation. *Europace* 2003;5:p1032–4.
- Siaplaouras S, Buob A, Rötter C, Böhm M, Jung J. Impact of biphasic cardioversion of atrial fibrillation on early recurrent atrial fibrillation: an efficacy study. *J Cardiovasc Electrophysiol* 2004;15:p895–7.
- Mittal S, Ayati S, Stein K, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. *Circulation* 2000;101:1282–7.
- Alatawi F, Gurevitz O, White R, et al. Prospective, randomized comparison of two biphasic waveforms for the efficacy and safety of transthoracic cardioversion of atrial fibrillation. *Heart Rhythm* 2005;2:p382–7.
- Kim M, Kim S, Park D, et al. Comparison of rectilinear biphasic waveform versus truncated exponential biphasic waveform energy for transthoracic cardioversion of atrial fibrillation. *Am J Cardiol* 2004;94:1438–40.
- Neal S, Ngarmukos T, Lessard D, Rosenthal L. Comparison of the efficacy and safety of two biphasic defibrillator waveforms for the conversion of atrial fibrillation to sinus rhythm. *Am J Cardiol* 2003;92:p810–4.
- Deakin CD, Connolly S, Wharmby J. A comparison of rectilinear and truncated exponential biphasic waveforms in elective cardioversion of atrial fibrillation: a prospective randomized controlled trial. *Resuscitation* 2006;67:p286–91.
- Ambler J, Deakin C. A randomized controlled trial of efficacy and ST-T segment following use of the Welch-Allyn MRLPIC biphasic waveform versus damped sine monophasic waveform for external DC cardioversion. *Resuscitation* 2006;72:p146–51.
- Deakin C, Ambler J. Post-shock myocardial stunning: a prospective randomized double-blind comparison of monophasic and biphasic waveforms. *Resuscitation* 2006;68:p329–33.
- Kmec J. Comparison of the effectiveness of damped sine wave monophasic and truncated exponential biphasic shocks in patients with persistent atrial fibrillation. *Kardiol* 2006;15:p265–78.







Citations 0

References 31

### Biphasic versus monophasic shock waveform for conversion of atrial fibrillation – The results of an international randomized, double-blind multicenter trial

[\[Show abstract\]](#)

Full-text · Article · Jun 2002





 Richard L Page  Richard E Kerber  James K Russell +11 more authors ...  
 Gust H Bardy

[Read full-text](#)

### External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: A randomized comparison of monophasic and biphasic shock energy application

[\[Show abstract\]](#)

Full-text · Article · Aug 2007





 Johannes C Manegold  Carsten W Israel  Joachim R Ehrlich  
+3 more authors ...  Stefan H Hohnloser

[Read full-text](#)

### Serum cardiac markers response to biphasic and monophasic electrical cardioversion for supraventricular tachyarrhythmia – a randomised study

[\[Show abstract\]](#)

Article · Sep 2006

 Roman Skulec  Jan Belohlavek  Tomas Kovarnik +4 more authors ...  
 Michael Aschermann





[Read](#)

[Show more](#)

People who read this publication also read

### HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis





Full-text · Article · Jan 2017

 Tongjing Xing  Hongtao Xu  Lin Cao  Maocong Ye

[Read full-text](#)

### Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis

Article · Jan 2017

 Rui Wang  Bobae V Kim  Madelon van Wely +7 more authors ...  
 Ben Willem J Mol

[Read](#)

**909: Comparative effectiveness of skin preparations for the prevention of wound infection and endometritis following cesarean delivery: a systematic review and network meta-analysis**

Article · Jan 2017 · BMJ Clinical Research

 Jared Roeckner  Luis Sanchez-Ramos

[Read](#)

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. Publisher conditions are provided by RoMEO. Differing provisions from policy or licence agreement may be applicable.

This publication is from a journal that may support self archiving. [Learn more](#)

© 2008-2017 researchgate.net. All rights reserved.

[About us](#) · [Help Center](#) · [Careers](#) · [Developers](#) · [News](#) · [Contact us](#) · [Privacy](#) · [Terms](#) · [Copyright](#) | [Advertising](#) · [Recruiting](#)